-
Views
-
Cite
Cite
Maureen P. Martin, Ying Qi, James J. Goedert, Shehnaz K. Hussain, Gregory D. Kirk, W. Keith Hoots, Susan Buchbinder, Mary Carrington, Chloe L. Thio, IL28B Polymorphism Does Not Determine Outcomes of Hepatitis B Virus or HIV Infection, The Journal of Infectious Diseases, Volume 202, Issue 11, 1 December 2010, Pages 1749–1753, https://doi.org/10.1086/657146
- Share Icon Share
Abstract
An IL28B haplotype strongly determines the outcome of natural and interferon-α treated hepatitis C virus (HCV) infection. To assess whether the polymorphism marking the haplotype (rs12979860) also affects other interferon-α responsive chronic viral illnesses, namely hepatitis B virus (HBV) and human immunodeficiency virus (HIV) type 1 infections, we genotyped 226 individuals with HBV persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P>.05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV.